Pomalidomide: Phase II data

In a Phase II trial in 35 patients with MM refractory to both Revlimid lenalidomide and Velcade bortezomib, pomalidomide plus dexamethasone led to an ORR of 54%, with 5 very good partial responses, 6 partial responses (PR) and 8 minor responses. Additionally, 6-month progression-free survival (PFS) and overall survival (OS) rates were 58% and 86%, respectively. Median PFS was 8 months. The most common grade 3/4 hematologic adverse events were neutropenia, anemia and thrombocytopenia. Patients received 2 mg daily pomalidomide on days 1-28 of each 28-day cycle and 40 mg daily oral dexamethasone on days 1, 8, 15 and 22. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...